Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

First patient undergoes pioneering stem-cell treatment for Parkinson's (opens in a new tab)

medicalxpress.com · 2026-10-30

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims
3

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 5Not checkedA patient has undergone pioneering stem-cell therapy to treat Parkinson's disease, in a world first following its conditional approval in Japan.View evidenceHide evidence

As statedworld first

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 5Not checkedSumitomo Pharma's treatment involves transplanting millions of induced pluripotent stem (iPS) cells into a patient's brain, after developing them into precursors of dopamine-producing brain cells.View evidenceHide evidence

As statedmillions of cells

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 5Not checkedJapanese regulators approved the therapy in March following a successful clinical trial.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 5Not checkedDuring a clinical trial, seven patients aged between 50 and 69 each received implants of either 5 million or 10 million cells on both sides of the brain; they were monitored for two years, no major adverse effects were found, and four patients showed improvements in symptoms.View evidenceHide evidence

As statedseven patients; 5 million or 10 million cells; two years; four patients

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 5Not checkedSumitomo Pharma plans to carry out transplants on 20 to 30 patients by March 2029 and says it is also carrying out a clinical trial in the United States.View evidenceHide evidence

As stated20 to 30 patients by March 2029

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

EFFECTS OF INTRA-ARTERIAL AND INTRAVENOUS TRANSPLANTATION OF INDUCED PLURIPOTENT STEM CELL-DERIVED NEURAL PROGENITOR CELLS ON ISCHEMIC STROKE RECOVERY IN RATS

2018 · Crossref

Source (opens in a new tab)

Explore all search results